Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Influence of VDR Polymorphisms on the Outcome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) within the Alovita Trial.

Estrella Carrillo-Cruz, MD, Teresa Caballero-Velázquez, MD PhD, Isabel Montero, MD, Fermin Sanchez-Guijo, MD PhD, Miguel Alcoceba, PhD, Christelle Marie Ferra I Coll, David Valcarcel, Rocio Parody, MD, Lucia Lopez Corral, Oriana López-Godino, Marian Cuesta, Francisco Marquez, Teresa Ramos, José Raúl Garcia-Lozano, José A. Pérez-Simón

Blood (2017) 130 (Supplement 1): 3251.

https://doi.org/10.1182/blood.V130.Suppl_1.3251.3251

Published: 2017

Journal Articles

Safety and Efficacy of Dasatinib Treatment Change for Patients Previosly Treated with Imatinib with Late Warning Response. Results from the Phase II, Open, Multicenter Dasapost Study

Valentín García-Gutierrez, MD, Felipe Casado, Fermín Sánchez-Guijo, MD PhD, Rosa M. Ayala, MD PhD, Concepcion Boque, PhD, Blanca Xicoy, MD, Isabel Montero, MD, Cesar Soto, Raquel De Paz, PhD, Joaquin Martinez-Lopez, Juan Luis Steegmann, MD

Blood (2016) 128 (22): 5450.

https://doi.org/10.1182/blood.V128.22.5450.5450

Published: 2016

Journal Articles

Prognostic Impact of Adverse Karyotype and Treatment in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Virginia Escamilla, Resident Physician, Jose Falantes, MD, Cristina Calderon, MD, Jose Gonzalez Campos, MD, Rosario Morales Camacho, MD PhD, Isabel Montero, MD, Rocio Parody, MD PhD, Ricardo Bernal, MD PhD, Ildefonso Espigado, MD PhD, Jose A Perez-Simón, MD PhD

Blood (2015) 126 (23): 5241.

https://doi.org/10.1182/blood.V126.23.5241.5241

Published: 2015

Journal Articles

Efficacy and Safety of Dasatinib in Late Suboptimal Response CML Patients a Its Relation with Lymphocytosis, Lymphocyte Migration and Chemokine Receptor Expression

Valentín García-Gutierrez, Beatriz Colom-Fernandez, Anna Kreutzman, PhD, Luis Felipe Casado, Fermín Sánchez-Guijo, MD, Rosa M. Ayala, MD PhD, Concepcion Boque, PhD, Blanca Xicoy, MD PhD, Isabel Montero, MD, Cesar Soto, Raquel De Paz, Joaquin Martinez Lopez, MDPhD, Cecilia Muñoz-Calleja, Juan Luis Steegmann, MD

Blood (2015) 126 (23): 4015.

https://doi.org/10.1182/blood.V126.23.4015.4015

Published: 2015

Journal Articles

Increased Gene Expression Involved in Angiogenesis, Metabolism and Cell Proliferation in Acute Myeloid Leukemia and myelodysplastic Syndromes Correlates with Adverse Clinical and Biological Features

Jose F Falantes, MD, Pablo Trujillo, Cristina Calderón, MD, Jose Gonzalez, MD, Maria Luz Martino, Isabel Montero, MD, Rocio Parody, MD, Ildefonso Espigado, MD, PhD, Jose Antonio Perez-Simón

Blood (2012) 120 (21): 1457.

https://doi.org/10.1182/blood.V120.21.1457.1457

Published: 2012

Journal Articles

Patterns of Infection in Patients with Myeloid Malignancies Receiving 5-Azacytidine: identification of Candidates for Antifungal Prophylaxis

Cristina Calderón, MD, Jose F Falantes, MD, Francisco Márquez-Malaver, MD, Jose González, MD, PhD, Maria Luz Martino, MD, Isabel Montero, MD, Ildefonso Espigado, MD, PhD, Jose Antonio Pérez-Simón, MD, PhD

Blood (2012) 120 (21): 4955.

https://doi.org/10.1182/blood.V120.21.4955.4955

Published: 2012

Journal Articles

Intensification of Chemotherapeutic Regimens and Hematopoietic Stem Cell Transplantation Are Responsible for Improved Overall Survival in Adult Acute Lymphoblastic Leukemia in a Single Center Over the Last Forty Years

Estrella Carrillo, MD, Nancy Rodriguez, Juan Francisco Dominguez, Jose Gonzalez, MD, Jose Francisco Falantes, MD, Isabel Montero, MD, M. Luz Martino, MD, Francisco Márquez-Malaver, Ricardo Parody, MD, Estefania Garcia-Guerrero, Jose Antonio Perez-Simón, Sr., MD, PhD, Ildefonso Espigado, MD, PhD

Blood (2011) 118 (21): 4227.

https://doi.org/10.1182/blood.V118.21.4227.4227

Published: 2011

Journal Articles

Prognostic Factors for Survival and Progression to Acute Myeloid Leukemia in Patients with Lower-Risk Myelodysplastic Syndromes. A New Scoring System

Jose F Falantes, MD, Cristina Calderón, MD, Ildefonso Espigado, MD, PhD, Dora Alonso, MD, Antonio Martín Noya, MD, PhD, Estrella Carrillo, MD, Maria Luz Martino, MD, Isabel Montero, MD, Jose González, MD, PhD, Jose Antonio Pérez-Simón, MD, PhD

Blood (2011) 118 (21): 1730.

https://doi.org/10.1182/blood.V118.21.1730.1730

Published: 2011

NARROW

Influence of VDR Polymorphisms on the Outcome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) within the Alovita Trial.

Safety and Efficacy of Dasatinib Treatment Change for Patients Previosly Treated with Imatinib with Late Warning Response. Results from the Phase II, Open, Multicenter Dasapost Study

Prognostic Impact of Adverse Karyotype and Treatment in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Efficacy and Safety of Dasatinib in Late Suboptimal Response CML Patients a Its Relation with Lymphocytosis, Lymphocyte Migration and Chemokine Receptor Expression

Increased Gene Expression Involved in Angiogenesis, Metabolism and Cell Proliferation in Acute Myeloid Leukemia and myelodysplastic Syndromes Correlates with Adverse Clinical and Biological Features

Patterns of Infection in Patients with Myeloid Malignancies Receiving 5-Azacytidine: identification of Candidates for Antifungal Prophylaxis

Intensification of Chemotherapeutic Regimens and Hematopoietic Stem Cell Transplantation Are Responsible for Improved Overall Survival in Adult Acute Lymphoblastic Leukemia in a Single Center Over the Last Forty Years

Prognostic Factors for Survival and Progression to Acute Myeloid Leukemia in Patients with Lower-Risk Myelodysplastic Syndromes. A New Scoring System

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only